MA-WOLTERS-KLUWER-HEALTH
17.11.2022 20:01:35 CET | Business Wire | Press release
Wolters Kluwer Health and NEJM Group have entered into an exclusive partnership to ensure that more researchers and clinicians around the world can access the growing family of NEJM Group journals. Building on years of collaboration, this expanded partnership positions NEJM Group journals for sustained global growth through Wolters Kluwer’s Ovid® medical research platform. Publications currently included are the New England Journal of Medicine, NEJM Evidence, NEJM Catalyst Innovations in Care Delivery, NEJM Journal Watch, the NEJM Archive, and future NEJM Group journals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117005838/en/
Wolters Kluwer Health will serve as the exclusive digital distributor of subscriptions to the New England Journal of Medicine, NEJM Evidence, NEJM Catalyst and NEJM Journal Watch (Graphic: Business Wire)
Unparalleled distribution critical to global reach
“The mission of NEJM Group is to advance medical knowledge from research to patient care, making the connections between developments in clinical science and clinical practice to improve healthcare quality and patient outcomes worldwide,” said David Sampson, Vice President of NEJM Group. “Wolters Kluwer’s worldwide sales and marketing presence creates additional opportunities to expand the reach of our content by delivering the NEJM Group portfolio of products to institutions globally.”
Through the partnership, institutional online subscribers to NEJM Group journals will be able to access their subscriber content both on NEJM Group sites and on the Ovid® medical research platform. Spanning over 150 publishers and more than 100 specialty areas, Ovid serves as the powerful, one-stop research software to help researchers, librarians, clinicians, and other healthcare professionals find timely and relevant medical information to make critical decisions to improve patient care, enhance ongoing research, and fuel new discoveries. With the addition of NEJM Group titles, Ovid users will be able to search and access the best research and information at the intersection of biomedical science and clinical practice, supporting improved patient care and clinical outcomes.
“The New England Journal of Medicine is one of the most highly respected and impactful medical periodicals in the world, drawing on a rich history, and cited more than any other journal,” said Vikram Savkar, Senior Vice President & General Manager, Medicine Segment, Health Learning, Research & Practice at Wolters Kluwer. “Leveraging Ovid’s market-leading search technology alongside Wolters Kluwer’s global sales and marketing reach will ensure more access to NEJM Group journals and archives around the world. Bringing together NEJM Group and Wolters Kluwer creates a global research powerhouse for clinicians seeking answers to care questions and researchers pursuing the next great discovery.”
The partnership builds on a strong foundation that has been fortified over many years of collaboration and a shared vision for the future of healthcare. Both NEJM Group and Wolters Kluwer maintain the highest standards for curation and peer review, and both support increased access to data and research globally. NEJM Group content around matters of public health importance, such as Covid-19, will continue to be available for free.
NEJM Group publications that will be distributed to institutions via Wolters Kluwer include:
- The New England Journal of Medicine, recognized as the world’s leading medical journal, delivering high-quality, peer-reviewed research and interactive clinical content to physicians, educators, researchers, and the global medical community.
- NEJM Evidence, which presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.
- NEJM Catalyst Innovations in Care Delivery, a peer-reviewed journal focusing on the latest innovations, big ideas, and practical solutions for healthcare delivery transformation.
- NEJM Journal Watch, which helps clinicians efficiently understand medical developments to improve patient care and foster professional development.
As a result of this distribution agreement, Wolters Kluwer Health Learning, Research & Practice will account for NEJM Group digital subscription revenues and related costs. The agreement has a positive but immaterial impact on the consolidated earnings of the Wolters Kluwer group.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2021 annual revenues of €4.8 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer Health provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005838/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wolters Kluwer Named Top Vendor Law Firm SaaS Solution Provider in the DACH Region for 202720.7.2026 09:00:00 CEST | Press release
Recognition highlights leadership position of Kleos in cloud-native legal practice management, earning the highest scores for customer satisfaction, value for money and customer recommendation among law firms in Germany, Austria and Switzerland. Wolters Kluwer’s Legal & Regulatory has been recognized as a top vendor for Law Firm SaaS Solutions in the DACH region for 2027, according to the latest Vendor Selection Matrix™ by Research in Action. Kleos, the company's cloud-native legal practice management platform, achieved a shared first-place position in the ranking and received the highest scores for customer satisfaction, value for money and customer recommendation among surveyed law firms in Germany, Austria and Switzerland. The recognition builds on the platform's earlier pan-European leadership position and reinforces Kleos' standing as one of Europe's leading legal practice management solutions. "We are proud to be recognized as a leading provider of Law Firm SaaS Solutions in the
IQM and Deutsche Bahn Demonstrate Quantum Algorithm for Railway Scheduling on Real Operational Data20.7.2026 08:00:00 CEST | Press release
A hybrid quantum-classical algorithm, executed end to end on IQM hardware, produced feasible schedules with Deutsche Bahn, the German rail operator, using a real operational dataset of 190 trips across five German cities. The approach runs on today’s hardware and is designed to improve automatically as quantum processors scale, offering enterprises a model for extracting value now, ahead of fault-tolerant computing. The collaboration reflects IQM’s push into enterprise adoption. The company has sold 24 quantum computers worldwide and listed on the Nasdaq Global Select Market and Nasdaq Helsinki in July 2026 under the ticker IQMX. IQM Quantum Computers (Nasdaq: IQMX), a global leader in full-stack superconducting quantum computers, today published the results of a research collaboration with Deutsche Bahn, Europe’s largest rail operator, exploring how quantum computing can improve railway scheduling. This press release features multimedia. View the full release here: https://www.busines
Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region20.7.2026 07:00:00 CEST | Press release
Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2 These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC region. The brand recently launched in Taiwan, will soon launch in Japan, and has received approval to launch in Singapore and South Korea, with planned market introduction in September and November, respectively. This expansion follows Alastin’s recent la
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 19:10:00 CEST | Press release
Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic ca
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 14:24:00 CEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
